Viola Franke speaks with ecancer at ESMO 2018 in Munich about results from a trial using engineered virotherapy talimogene laherparepvec (T-VEC) in early metastatic melanoma.

She describes the significant response rates and low toxicity in this early trial, with followups planned to monitor the ongoing survival of these patients.

For more on melanoma news from ESMO, watch our interview with Dr Alexander van Aakooi.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.